San Antonio Breast Cancer Symposium

• “A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody–Drug Conjugate, in Patients with HER2+ Metastatic Breast Cancer who were Previously Treated with an Anthracycline, a Taxane, Capecitabine, Lapatinib, and Trastuzumab."
  
  Poster presented.

American Society of Hematology

• “Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma” (abstract #1862).
  
  Poster presented.



• “Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis (abstract #2883 ).
  
  Poster presented.



• “Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)” (abstract #585).
  
  Slides shown.

AACR-NCI-EORTC

• “The effect of linker on target cell catabolism and PK/PD of trastuzumab-maytansinoid conjugates” (abstract #A149).
  Poster presented.



• “Clinical experience of IMGN901 (BB-10901, huN901-DM1) in patients with Merkel cell carcinoma (MCC)” (abstract #B237).
  Poster presented.



• “Potent antigen-specific anti-tumor activity observed with antibody-drug conjugates (ADCs) made using a new class of DNA-crosslinking agents” (abstract #B126).
  Poster presented.



• “Designing potent antibody-drug conjugates: The impact of lysosomal processing efficiency and conjugate linker selection on anticancer activity” (abstract #B120).
  Poster presented.